Welcome to LookChem.com Sign In|Join Free
  • or
Benzeneethanamine, N,N-bis(2-chloroethyl)-, hydrochloride is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

100249-12-5

Post Buying Request

100249-12-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

100249-12-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 100249-12-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,2,4 and 9 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 100249-12:
(8*1)+(7*0)+(6*0)+(5*2)+(4*4)+(3*9)+(2*1)+(1*2)=65
65 % 10 = 5
So 100249-12-5 is a valid CAS Registry Number.

100249-12-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name N,N-bis(2-chloroethyl)-2-phenylethanamine,hydrochloride

1.2 Other means of identification

Product number -
Other names bis-(2-chloro-ethyl)-phenethyl-amine,hydrochloride

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:100249-12-5 SDS

100249-12-5Relevant academic research and scientific papers

Photoactive chemosensors 3: A unique case of fluorescence enhancement with Cu(II)

Kaur, Sukhdeep,Kumar, Subodh

, p. 2840 - 2841 (2002)

Chemosensor (4a) shows fluorescence enhancement with Cu(II) and can estimate 1-300 μM Cu(II) by using fluorescence (1-20 μM) and UV-Vis (10-300 μM) spectroscopic techniques. Ni(II), Cd(II), Zn(II), Ag(I) and Hg(II) do not interfere in fluorescence studies and only Ag(I) and Hg(II) interfere in UV-Vis studies.

Synthesis and structure - Activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis

Aranapakam, Venkatesan,Davis, Jamie M.,Grosu, George T.,Baker, Jannie,Ellingboe, John,Zask, Arie,Levin, Jeremy I.,Sandanayaka, Vincent P.,Du, Mila,Skotnicki, Jerauld S.,DiJoseph, John F.,Sung, Amy,Sharr, Michele A.,Killar, Loran M.,Walter, Thomas,Jin, Guixian,Cowling, Rebecca,Tillett, Jeff,Zhao, Weiguang,McDevitt, Joseph,Xu, Zhang Bao

, p. 2376 - 2396 (2007/10/03)

The matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases that play a key role in both physiological and pathological tissue degradation. In our preceding paper, we have reported on a series of novel and orally active N-hydroxy-α-phenylsulfonylacetamide derivatives. However, these compounds had two drawbacks (moderate selectivity and chirality issues). To circumvent these two problems, a series of novel and orally active N-substituted 4-benzenesulfonylpiperidine-4-carboxylic acid hydroxyamide derivatives have been synthesized. The present paper deals with the synthesis and SAR of these compounds. Among the several compounds synthesized, derivative 55 turned out to be a potent, selective, and an orally active MMP inhibitor in the clinically relevant advanced rabbit osteoarthritis model. Detailed pharmacokinetics and metabolism data are described.

1,4-(diphenlyalkyl) piperazine derivatives

-

, (2008/06/13)

This invention relates to novel compounds of the formula [I], STR1 wherein R 1 and R 2 are the same or different and each represents a lower alkoxy group; A and B are the same or different and each represents a lower alkylene group.The compounds of this i

(N-phthalimidoalkyl) piperidines useful as treatments for psychosis

-

, (2008/06/13)

There is described novel (N-phthalimidoalkyl) piperidine compounds which exhibit selective sigma-receptor antagonism and therefore are useful in the treatment of physiological or drug induced psychosis and dyskinesia in a mammal. Also described are pharmaceutical compositions containing sigma selective compounds and methods of using these compositions for treating physiological or drug induced psychosis or dyskinesia in a mammal. Further provided are methods for preparing the compounds of this invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 100249-12-5